Home News and Analysis PE Deals Inside the exit: Signet makes approximately 3x in RK Pharma exit

Inside the exit: Signet makes approximately 3x in RK Pharma exit

The generic drugs that RK Pharma focuses on cover a spectrum of areas, among them anemia, ophthalmology, oncology, inflammatory diseases and more.

13 June 2023

You should only be asked to sign in once. Not the case? Click here

Register now

Get limited access to our industry news, analysis and data, plus regular email updates

Email address

First name

first name

Last name

last name

Organisation

Country Phone number Job title

Job Title

To register, please review and accept our terms and conditions and privacy notice. I accept: sourceRegistration

Not for publication, email or dissemination